
Lil Rel Credits Five-Year Lifestyle Change for Weight Loss
The comedian says he lost weight through sobriety, exercise and therapy, and denies using Ozempic.
Live Poll
Do you think people owe the public an explanation for how they lost weight?
U.S. weight loss coverage follows obesity research, medication approvals and the policy and insurance decisions that shape access to treatment across the country. Reporting takes in dietary science, surgical options and the cultural conversations around weight.

The comedian says he lost weight through sobriety, exercise and therapy, and denies using Ozempic.
Live Poll
Do you think people owe the public an explanation for how they lost weight?
November 8, 2026
Political Weight Talk Is No Guide to Losing WeightPublic comments on candidates' bodies do not replace medical advice about weight-loss methods and goals.
November 8, 2026
Jenna Jameson Shares Weight Loss After Quitting KetoJameson's 125-pound progress is one person's account, not evidence that stopping keto works for most people.
November 7, 2026
Semaglutide Shows Liver and Weight Gains in MASHReal-world U.S. data suggest adults with MASH saw greater weight and liver enzyme declines on semaglutide 2.4 mg.
November 6, 2026
FDA Warns of Risks in Compounded GLP-1 DrugsAdults using compounded semaglutide or tirzepatide face products that the FDA has not reviewed for safety or quality.
November 6, 2026
Trump's Fitness Claims Draw Reporter ConfrontationRecorded weight and heart-rate figures are part of an ongoing public debate about the president's physical condition.
November 6, 2026
Weight Programs Pair GLP-1 Drugs With CoachingWW's clinical subscriptions grew 48% this quarter as its behavioral program shrank, showing medication-linked weight care gaining ground.
November 6, 2026
Medicare Patients Get GLP-1 Weight Drugs at $50Eligible Part D beneficiaries can now access certain GLP-1 medications for weight management at $50 a month under the Bridge Program.
November 4, 2026
Obesity Drug Candidates Advance Toward Phase 3Adults with obesity should know these oral and injectable candidates are still in clinical trials and not yet available.
November 4, 2026
Experimental Obesity Drug to Show Muscle-Sparing DataAdults managing weight should know these early findings come from mouse studies and the drug is not yet approved for use in people.
November 3, 2026
Monthly Olanzapine Injection Approved; Weight Gain NotedAdults with schizophrenia gain a once-monthly option, though weight gain was the most common long-term side effect in trial participants.
National reporting follows medication approvals and long-term outcome data, obesity prevalence research, dietary intervention studies and the growing role of weight-loss surgery. New York, Los Angeles, Chicago, Houston and Phoenix anchor coverage of where clinical activity and program development are most concentrated nationally. Insurance coverage of newer drug approvals has become a recurring subject, since formulary decisions vary widely and determine which patients can use approved therapies. The relationship between approved treatments, access and long-term outcomes is treated as an open question rather than a settled one.